文献速递血液净化与透析

导管相关血流感染预防装置的整群随机试验

Cluster-Randomized Trial of Devices to Prevent Catheter-Related Bloodstream Infection.
PubMed 文献 · J Am Soc Nephrol · 2018-02-22

结果显示ClearGuard组血流感染率显著低于Tego+Curos组(0.28 vs 0.75 每1000导管日,P=0.001),且无器械相关不良事件。

要点

  • ClearGuard HD抗菌屏障帽显著降低透析患者导管相关血流感染率。
  • 与Tego连接器加Curos帽相比,ClearGuard组每1000导管日阳性血培养率更低。
  • 研究中未报告器械相关不良事件。

核心结论

  • 在血液透析使用中心静脉导管的患者中,ClearGuard HD抗菌屏障帽相比Tego连接器加Curos帽显著降低导管相关血流感染率。

研究设计与样本

  • 纳入所有使用中心静脉导管的成人透析患者(对肝素或氯己定过敏者除外),共1671人,累积超过183,000个导管日。

主要发现

  • 干预前3个月磨合期两组血流感染率相似(P=0.8)。
  • 13个月干预期间,ClearGuard组血流感染率为0.28例/1000导管日,显著低于Tego+Curos组的0.75例/1000导管日(P=0.001)。
  • 未报告器械相关不良事件。

关键数值与推荐

  • 主要结局为阳性血培养率,作为血流感染率的指标,在整群水平计算并校正设施集群效应。

临床怎么用

  • 对于使用中心静脉导管的血液透析患者,可优先选用ClearGuard HD抗菌屏障帽以降低导管相关血流感染风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Central venous catheters (CVCs) contribute disproportionately to bloodstream infection (BSI) and, by extension, to infection-related hospitalization, mortality, and health care costs in patients undergoing dialysis. Recent product advancements may reduce BSIs, but a sufficiently powered comparative-effectiveness study is needed to facilitate evidence-based patient care decisions. In a 13-month, prospective, cluster-randomized, open-label trial, we compared BSI rates in facilities using ClearGuard HD antimicrobial barrier caps (ClearGuard group) with those in facilities using Tego hemodialysis connectors plus Curos disinfecting caps (Tego+Curos group). Forty DaVita dialysis facilities in the United States were pair-matched by BSI rate, number of patients using CVCs, and geographic location, and then cluster randomized 1:1. We enrolled all adult patients undergoing dialysis with CVCs at these facilities, except those allergic to heparin or chlorhexidine. Overall, 1671 patients participated in the study, accruing >183,000 CVC-days. The study outcome was positive blood culture (PBC) rate as an indicator of BSI rate. We calculated results at the cluster level and adjusted for the facility cluster effect. During a 3-month run-in period immediately before study interventions, the groups had similar BSI rates (P=0.8). During the 13-month intervention period that immediately followed, the ClearGuard group had a BSI rate significantly lower than that of the Tego+Curos group (0.28 versus 0.75 PBCs per 1000 CVC-days, respectively; P=0.001). No device-related adverse events were reported. In conclusion, compared with Tego connectors plus Curos caps, ClearGuard HD antimicrobial barrier caps significantly lowered the rate of catheter-related BSIs in patients undergoing hemodialysis using CVCs, representing an important advancement in hemodialysis patient care.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Brunelli SM, Van Wyck DB, Njord L, et al. Cluster-Randomized Trial of Devices to Prevent Catheter-Related Bloodstream Infection. J Am Soc Nephrol. 2018. PMID: 29472415. doi:10.1681/ASN.2017080870

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。